Apellis Pharmaceuticals (APLS) Stock Forecast, Price & News

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Apellis Pharmaceuticals in the last twelve months. There are currently 5 hold ratings, 9 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" APLS shares.
View APLS analyst ratings or view top-rated stocks.

15 equities research analysts have issued 1 year price objectives for Apellis Pharmaceuticals' stock. Their APLS share price forecasts range from $29.00 to $141.00. On average, they anticipate the company's share price to reach $66.13 in the next year. This suggests a possible upside of 66.4% from the stock's current price.
View analysts price targets for APLS or view top-rated stocks among Wall Street analysts.

Apellis Pharmaceuticals' stock was trading at $51.71 at the beginning of the year. Since then, APLS shares have decreased by 23.1% and is now trading at $39.75.
View the best growth stocks for 2023 here.

Apellis Pharmaceuticals saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 13,610,000 shares, an increase of 10.6% from the August 31st total of 12,310,000 shares. Based on an average trading volume of 4,730,000 shares, the days-to-cover ratio is currently 2.9 days.
View Apellis Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our APLS earnings forecast.

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) issued its quarterly earnings data on Monday, July, 31st. The company reported ($1.02) EPS for the quarter, beating the consensus estimate of ($1.35) by $0.33. The company had revenue of $95 million for the quarter, compared to analyst estimates of $70.38 million. Apellis Pharmaceuticals had a negative net margin of 356.02% and a negative trailing twelve-month return on equity of 212.82%. The business's quarterly revenue was up 482.8% on a year-over-year basis. During the same period last year, the firm earned ($1.46) earnings per share.

ETFs with the largest weight of Apellis Pharmaceuticals (NASDAQ:APLS) stock in their portfolio include Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Jacob Forward ETF (JFWD), Vanguard Russell 2000 Growth ETF (VTWG), Principal Healthcare Innovators ETF (BTEC) and Vanguard Small-Cap Growth ETF (VBK).Harbor Health Care ETF (MEDI).

18 employees have rated Apellis Pharmaceuticals Chief Executive Officer Cedric Francois on Glassdoor.com. Cedric Francois has an approval rating of 100% among the company's employees. This puts Cedric Francois in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 74.0% of employees surveyed would recommend working at Apellis Pharmaceuticals to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Apellis Pharmaceuticals investors own include AbbVie (ABBV), OPKO Health (OPK), Fate Therapeutics (FATE), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Amarin (AMRN), Anavex Life Sciences (AVXL), Axsome Therapeutics (AXSM) and BioXcel Therapeutics (BTAI).

(APLS) raised $150 million in an initial public offering (IPO) on Thursday, November 9th 2017. The company issued 10,700,000 shares at a price of $13.00-$15.00 per share. Citigroup, J.P. Morgan and Evercore ISI served as the underwriters for the IPO.

Apellis Pharmaceuticals trades on the NASDAQ under the ticker symbol "APLS."

Apellis Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (4.88%), State Street Corp (1.94%), Jennison Associates LLC (1.67%), Geode Capital Management LLC (1.27%), Point72 Asset Management L.P. (1.05%) and Artal Group S.A. (0.89%). Insiders that own company stock include A Sinclair Dunlop, Adam J Townsend, Alec Machiels, Cedric Francois, David O Watson, Federico Grossi, James George Chopas, Jeffrey Eisele, Karen Lewis, Lukas Scheibler, Mark Jeffrey Delong, Morningside Venture Investment, Nicole D Perry, Nur Nicholson, Pascal Deschatelets, Timothy Eugene Sullivan, Victoria L Brown and Victoria L Brown.
View institutional ownership trends.

Shares of APLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of APLS stock can currently be purchased for approximately $39.75.

Apellis Pharmaceuticals (NASDAQ:APLS) has a market capitalization of $4.68 billion and generates $75.42 million in revenue each year. The company earns $-652,170,000.00 in net income (profit) each year or ($5.83) on an earnings per share basis.

The company employs 767 workers across the globe.

Apellis Pharmaceuticals' mailing address is 100 FIFTH AVENUE, WALTHAM MA, 02451. The official website for the company is www.apellis.com. The company can be reached via phone at (617) 977-5700 or via email at investors@apellis.com.